M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
US biogenetics company Klotho Neurosciences, Inc. (NASDAQ:KLTO) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to KLTO-202, its lead gene therapy candidate for the treatment of amyotrophic lateral sclerosis (ALS).
The designation...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search